Symptom relief was more rapid with ruxolitinib versus best available therapy, but adverse effects were more frequent.
Substituting obinutuzumab for rituximab during induction chemotherapy did not improve outcomes.
Patients show an elevated risk for myocardial infarction and ischemic stroke 6 months after cancer diagnosis.
Response rates were higher with decitabine, especially in higher-risk patients.
First-line nivolumab did not prolong progression-free survival in chemo-naive patients with stage IV or recurrent PD-L1–positive non–small-cell lung cancer.
Surgery did not significantly lower all-cause or prostate cancer mortality.
Idarucizumab rapidly reverses the effects of dabigatran in bleeding patients and in those undergoing urgent procedures.
Overall survival was improved by adding midostaurin to standard induction chemotherapy.
Highlights of new treatments for myeloma, leukemia, and lymphoma
Emicizumab prevented bleeding and improved health-related quality of life.
Prof. Dr. med. Florian Otto
Tumor- und Brustzentrum ZeTuP, St. Gallen
E-Mail: E-Mail anzeigen
Immuntherapie ist in aller Munde. Checkpoint-Inhibitoren werden bei praktisch allen onkologischen Erkrankungen erprobt und erweisen sich häufig als wirksam – zumindest für eine gewisse Zeit. Aber wie entwickelt sich eine Resistenz? Dieser Frage sind Zaretsky und Kollegen im Kontext von vier Melanompatienten unter Pembrolizumab-Therapie nachgegangen und haben Defekte im Interferon-Signalweg sowie der Antigenpräsentation in den Tumorzellen gefunden.
Mortality was similar with active monitoring, prostatectomy, or radiotherapy during 10 years of follow-up.
Pregnant women with inherited thrombophilia have increased risk for VTE, independent of a family history of VTE.
The use of >12 serum tumor marker tests and/or 4 radiographic imaging tests per year provided no survival advantage.
Adding epirubicin to fluorouracil/platinum-based chemotherapy resulted in greater toxicity and no clear improvement in response.
Andexanet reduced anti–factor Xa activity and restored effective hemostasis in patients with major bleeding.
A 70-gene signature identified patients with high clinical risk and low molecular risk who achieved a 5-year survival rate of 94.7% without chemotherapy.
Declines in light chain levels were achieved in heavily pretreated patients.
The HER2-targeted combination regimen of trastuzumab and lapatinib may have activity in HER2-positive, chemotherapy-refractory disease.
Mutations preventing interferon-receptor signaling and antigen presentation are linked to acquired resistance.
Overall survival was significantly better with S-1 versus gemcitabine.